Trimethoprim

From WikiProjectMed
Jump to navigation Jump to search
Trimethoprim
Structural formula of trimethoprim
Ball-and-stick model of the trimethoprim molecule
Names
Pronunciation/trˈmɛθəprɪm/
Trade namesProloprim, Monotrim, Triprim, others
  • 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine
Clinical data
WHO AWaReAccess
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
use
Oral
Defined daily dose0.4 g (parenteral) or
0.4 g (by mouth) [1]
External links
AHFS/Drugs.comMonograph
MedlinePlusa684025
Legal
License data
Legal status
Pharmacokinetics
Bioavailability90–100%
Protein binding44%
Metabolismliver
Elimination half-life8–12 hours
ExcretionUrine (50–60%), faeces (4%)
Chemical and physical data
FormulaC14H18N4O3
Molar mass290.323 g·mol−1
3D model (JSmol)
  • Nc1nc(N)ncc1Cc(cc2OC)cc(OC)c2OC
  • InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18) checkY
  • Key:IEDVJHCEMCRBQM-UHFFFAOYSA-N checkY

Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections.[2] Other uses include for middle ear infections and travelers' diarrhea.[2] With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS.[2][3] It is taken by mouth.[2]

Common side effects include nausea, changes in taste, and rash.[4][2] Rarely it may result in blood problems such as not enough platelets or white blood cells.[2] It may cause sun sensitivity.[2] There is evidence of potential harm during pregnancy in some animals but not humans.[5] It works by blocking folate metabolism via dihydrofolate reductase in some bacteria which results in their death.[2]

Trimethoprim was first used in 1962.[6] It is on the World Health Organization's List of Essential Medicines.[7] It is available as a generic medication and the tablet form is not very expensive.[8][9] In the United States, ten days of treatment costs about $21.[2]

Medical uses

It is primarily used in the treatment of urinary tract infections, although it may be used against any susceptible aerobic bacterial species.[10] It may also be used to treat and prevent Pneumocystis jirovecii pneumonia.[10] It is generally not recommended for the treatment of anaerobic infections such as Clostridium difficile colitis (the leading cause of antibiotic-induced diarrhea).[10] Trimethoprim has been used in trials to treat retinitis.[11]

Resistance to trimethoprim is increasing, but it is still a first line antibiotic in many countries.[12] It is in the 'access' group of the WHO AWaRe Classification.[13]

Spectrum of susceptibility

Cultures and susceptibility tests should be done to make sure bacteria are treated by trimethoprim.[14][15]

Dosage

The defined daily dose is 0.4 g (parenteral) or 0.4 g (by mouth).[1] The dose in adults for a urinary tract infection is 100 mg twice per day for 10 days.[2]

Side effects

Common

  • Nausea
  • Change in taste
  • Vomiting
  • Diarrhea
  • Rash
  • Sun sensitivity
  • Itchiness[16][17]

Rare

Contraindications

Liver and kidney problems

10–20% of trimethoprim is metabolized by the liver and the rest is excreted in the urine. Therefore, trimethoprim should be used with caution in individuals with kidney and liver impairments. Dosage adjustment is not needed for liver impairment but should be adjusted for kidney impairment.[23]

Pregnancy

Based on studies that show that trimethoprim crosses the placenta and can affect folate metabolism, there has been growing evidence of the risk of structural birth defects associated with trimethoprim, especially during the first trimester of pregnancy.[24] It may be involved in a reaction similar to disulfiram when alcohol is consumed after it is used, in particular when used in combination with sulfamethoxazole.[25][26] The trophoblasts in the early fetus are sensitive to changes in the folate cycle. A recent study has found a doubling in the risk of miscarriage in women exposed to trimethoprim in the early pregnancy.[27]

Mechanism of action

Staphylococcus aureus DHFR in complex with NADPH and trimethoprim PDB entry 2W9G [28]

Trimethoprim binds to dihydrofolate reductase and inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF).[29] THF is an essential precursor in the thymidine synthesis pathway and interference with this pathway inhibits bacterial DNA synthesis.[29] Trimethoprim's affinity for bacterial dihydrofolate reductase is several thousand times greater than its affinity for human dihydrofolate reductase.[29] Sulfamethoxazole inhibits dihydropteroate synthase, an enzyme involved further upstream in the same pathway.[29] Trimethoprim and sulfamethoxazole are commonly used in combination due to possible synergistic effects, and reduced development of resistance.[29] This benefit has been questioned.[30]

Tetrahydrofolate synthesis pathway

History

Trimethoprim was first used in 1962.[6] In 1972, it was used in Finland, to prevent urinary tract infections.[6]

Its name is derived from trimethyloxy-pyrimidine.

Social and cultural

Cost

It is available as a generic medication and is not very expensive.[8] The liquid form, however, is much more expensive.[8] 14 tablets of trimethoprim 200mg tablets costs the NHS in the UK less than a pound.[31]

References

  1. 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 24 August 2019. Retrieved 22 September 2020.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 "Trimethoprim". The American Society of Health-System Pharmacists. Archived from the original on 2015-09-24. Retrieved Aug 1, 2015.
  3. Masur, H; Brooks, JT; Benson, CA; Holmes, KK; Pau, AK; Kaplan, JE; National Institutes of, Health; Centers for Disease Control and, Prevention; HIV Medicine Association of the Infectious Diseases Society of, America (May 2014). "Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America". Clinical Infectious Diseases. 58 (9): 1308–11. doi:10.1093/cid/ciu094. PMC 3982842. PMID 24585567.
  4. Ritter, James M.; Flower, Rod; Henderson, Graeme; Loke, Yoon Kong; Robinson, Emma; Fullerton, James (2024). "52. Antibacterial drugs". Rang & Dale's Pharmacology (10th ed.). Elsevier. pp. 706–707. ISBN 978-0-7020-7448-6. Archived from the original on 2024-02-12. Retrieved 2024-01-30.
  5. "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
  6. 6.0 6.1 6.2 Huovinen, P (1 June 2001). "Resistance to trimethoprim-sulfamethoxazole". Clinical Infectious Diseases. 32 (11): 1608–14. doi:10.1086/320532. PMID 11340533.
  7. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. 8.0 8.1 8.2 Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (2nd ed.). Elsevier. pp. 212–213. ISBN 978-0-7020-7442-4. Archived from the original on 2021-05-22. Retrieved 2021-11-09.
  9. Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 113. ISBN 9781284057560.
  10. 10.0 10.1 10.2 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  11. Pradhan E, Bhandari S, Gilbert RE, Stanford M (May 2016). "Antibiotics versus no treatment for toxoplasma retinochoroiditis" (PDF). Cochrane Database Syst Rev (5): CD002218. doi:10.1002/14651858.CD002218.pub2. PMID 27198629. Archived (PDF) from the original on 2018-07-22. Retrieved 2019-09-03.
  12. "Three-day courses of antibiotics for uncomplicated urinary tract infection | Guidance and guidelines | NICE". Archived from the original on 2015-12-08. Retrieved 2015-12-30.
  13. Zanichelli, Veronica; Sharland, Michael; Cappello, Bernadette; Moja, Lorenzo; Getahun, Haileyesus; Pessoa-Silva, Carmem; Sati, Hatim; van Weezenbeek, Catharina; Balkhy, Hanan; Simão, Mariângela; Gandra, Sumanth; Huttner, Benedikt (1 April 2023). "The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance". Bulletin of the World Health Organization. 101 (4): 290–296. doi:10.2471/BLT.22.288614. ISSN 0042-9686. Archived from the original on 7 May 2023. Retrieved 17 November 2023.
  14. "DailyMed - TRIMETHOPRIM- trimethoprim tablet". dailymed.nlm.nih.gov. Archived from the original on 2015-09-30. Retrieved 2015-11-04.
  15. "DailyMed - PRIMSOL- trimethoprim hydrochloride solution". dailymed.nlm.nih.gov. Archived from the original on 2015-11-17. Retrieved 2015-11-04.
  16. "PROLOPRIM® (trimethoprim)100-mg and 200-mg Scored Tablets". dailymed.nlm.nih.gov. Archived from the original on 2015-11-17. Retrieved 2015-11-04.
  17. Ellenhorn, M.J.; S. Schonwald; G. Ordog; J. Wasserberger. American Hospital Formulary Service- Drug Information 2002. Baltimore, MD: Williams and Wilkins. p. 236.
  18. MICROMEDEX Thomson Health Care. USPDIpublisher = Thomson Health. Drug Information for the Health Care Professional. 22nd ed. Volume 1. CareGreenwood Village, CO. 2002 p. 2849.{{cite book}}: CS1 maint: location (link)
  19. Choi, Michael J.; Fernandez, Pedro C.; Patnaik, Asit; Coupaye-Gerard, Brigitte; D'Andrea, Denise; Szerlip, Harold; Kleyman, Thomas R. (1993-03-11). "Trimethoprim-Induced Hyperkalemia in a Patient with AIDS". New England Journal of Medicine. 328 (10): 703–706. doi:10.1056/NEJM199303113281006. ISSN 0028-4793. PMID 8433730.
  20. Naderer, O.; Nafziger, A. N.; Bertino, J. S. (1997-11-01). "Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions". Antimicrobial Agents and Chemotherapy. 41 (11): 2466–2470. doi:10.1128/AAC.41.11.2466. ISSN 0066-4804. PMC 164146. PMID 9371351.
  21. Kimmitt PT, Harwood CR, Barer MR (2000). "Toxin Gene Expression by Shiga Toxin-producing Escherichia coli: The Role of Antibiotics and the Bacterial SOS Response". Emerg Infect Dis. 6 (5): 458–465. doi:10.3201/eid0605.000503. PMC 2627954. PMID 10998375.
  22. "DailyMed - PRIMSOL- trimethoprim hydrochloride solution". dailymed.nlm.nih.gov. Archived from the original on 2015-11-17. Retrieved 2015-11-04.
  23. "DailyMed - TRIMETHOPRIM- trimethoprim tablet". dailymed.nlm.nih.gov. Archived from the original on 2015-09-30. Retrieved 2015-11-04.
  24. Sivojelezova, Anna; Einarson, Adrienne; Shuhaiber, Samar; Koren, Gideon (2003-09-01). "Trimethoprim-sulfonamide combination therapy in early pregnancy". Canadian Family Physician. 49: 1085–1086. ISSN 0008-350X. PMC 2214286. PMID 14526858.
  25. Edwards DL, Fink PC, van Dyke PO (1986). "Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole". J Clinical Pharmacy. 5 (12): 999–1000. PMID 3492326. Archived from the original on 2009-01-24.
  26. Heelon MW, White M (1998). "Disulfiram cotrimoxazole reaction". J Pharmacotherapy. 18 (4): 869–870. PMID 9692665. Archived from the original on 2009-01-24.
  27. Andersen JT, Petersen M, Jimenez-Solem E, Broedbaek K, Andersen EW, Andersen NL, Afzal S, Torp-Pedersen C, Keiding N, Poulsen HE (2013). "Trimethoprim use in early pregnancy and the risk of miscarriage: a register-based nationwide cohort study". Epidemiology and Infection. 141 (8): 1749–1755. doi:10.1017/S0950268812002178. PMID 23010291.
  28. Heaslet, H.; Harris, M.; Fahnoe, K.; Sarver, R.; Putz, H.; Chang, J.; Subramanyam, C.; Barreiro, G.; Miller, J. R. (2009). "Structural comparison of chromosomal and exogenous dihydrofolate reductase fromStaphylococcus aureusin complex with the potent inhibitor trimethoprim". Proteins: Structure, Function, and Bioinformatics. 76 (3): 706–717. doi:10.1002/prot.22383. PMID 19280600.
  29. 29.0 29.1 29.2 29.3 29.4 Brogden, RN; Carmine, AA; Heel, RC; Speight, TM; Avery, GS (June 1982). "Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections". Drugs. 23 (6): 405–30. doi:10.2165/00003495-198223060-00001. PMID 7049657.
  30. Brumfitt, W; Hamilton-Miller, JM (December 1993). "Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines". Journal of Chemotherapy. 5 (6): 465–9. doi:10.1080/1120009X.1993.11741097. PMID 8195839.
  31. BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 607-608. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

External links

External sites:
Identifiers: